Stem Cell Therapy Success Rates: What the Studies Actually Say

ByFarhan Feroz Ali

Clinic websites routinely advertise success rates of 80% to 90%. Published randomised trials tell a substantially different story. Understanding the gap between the two numbers is the most useful thing you can learn before deciding.

Where clinic success rates come from

Almost universally, from internal patient surveys with no control group.

A clinic treats 100 patients, asks them afterwards whether they feel better, and 85 say yes. That becomes "85% success rate." Every step of that process inflates the number:

  • No control group. There is no comparison to patients who received a placebo injection, so improvement from any cause is credited to the treatment.
  • Regression to the mean. People seek treatment when symptoms peak. Symptoms fluctuate. Many would have improved anyway.
  • Placebo and contextual effects. An expensive, high-ritual, hopeful procedure produces genuine symptom improvement independent of the active ingredient.
  • Response bias. Patients who spent $15,000 and were treated warmly are reluctant to report failure. Those who did poorly often stop answering.
  • Selective timing. Asking at six weeks, when short-term effects peak, rather than at twelve months.

None of this requires dishonesty. It requires only that nobody design the measurement rigorously — and there is no incentive to.

What controlled trials found

Knee osteoarthritis. The most informative evidence available. A 2025 systematic review and meta-analysis pooled eight randomised controlled trials covering 467 patients, comparing MSC injections against inert placebo. It found that approximately 63% of pain reduction and 61% of functional improvement at six months was attributable to contextual effects rather than the cells. At twelve months, roughly 50% of pain relief and 66% of functional gain remained attributable to contextual factors. The authors concluded the cells themselves confer "only a modest incremental benefit," and rated the certainty of evidence as low.

The authors framed this as resolving an "efficacy paradox": patients genuinely do improve, substantially — which is why clinics report high success rates in good faith — but most of that improvement is not caused by the cells.

Aggressive relapsing-remitting MS. A different picture entirely. In the MIST randomised trial, progression-free survival at five years was approximately 90% for AHSCT compared with about 25% for continued disease-modifying therapy. Comparative studies against alemtuzumab consistently favoured AHSCT. Contemporary transplant-related mortality is around 0.3%, down from 3.6% before 2005. This is real, replicated, randomised evidence — for a serious hospital procedure in carefully selected patients, not a clinic infusion.

COPD, autism, anti-ageing. No high-quality randomised evidence of benefit exists. Claimed success rates for these conditions come entirely from uncontrolled sources.

What "success" is even measuring

Ask any clinic quoting a percentage: success at what, measured how, at what time point, compared with what?

Meaningful outcome measures exist — WOMAC and KOOS scores for knee osteoarthritis, EDSS for MS, validated pain scales. If a clinic cannot tell you which instrument it used, it did not use one.

Improvement is real even when the cause is not what you were told

The meta-analysis finding is often misread as "patients imagine it." That is wrong. The pain relief people experience is genuine and measurable. What the data suggests is that most of it comes from expectation, the therapeutic ritual, attentive care, and natural fluctuation — not from the cells. The relief is real. The attribution is not. That distinction matters when the attribution costs $15,000.

What to ask instead of "what’s your success rate?"

  1. Which published randomised controlled trial supports this for my condition?
  2. What validated outcome measure do you use, and at what time points?
  3. What percentage of your patients do you still have follow-up data for at twelve months?
  4. How many of your patients reported no benefit?
  5. Has your outcome data been independently reviewed or published?

A clinic that answers question four honestly is worth taking seriously.

Sources

  1. Contextual effects of mesenchymal stem cell injections for knee osteoarthritis: systematic review and meta-analysis of randomised controlled trials. Frontiers in Medicine, 2025.
  2. Burt RK et al. Effect of non-myeloablative HSCT vs continued DMT on disease progression in relapsing-remitting MS (MIST trial). JAMA, 2019.
  3. Autologous haematopoietic stem cell transplantation for MS and NMOSD — ECTRIMS and EBMT recommendations. Nature Reviews Neurology, 2024.

Not sure whether this is right for you?

Tell us about your condition and we will send you our free clinic-vetting checklist, an honest summary of the evidence for your situation, and — where they exist — free clinical trials you may be eligible for. Get matched with a vetted clinic

Medical disclaimer

This article is for general information and is not medical advice. We are not a healthcare provider and do not diagnose or treat any condition. Most stem cell treatments discussed here are not FDA approved for these uses, outcomes vary, and no result is guaranteed. Always speak with a licensed physician who knows your history. See our medical disclaimer and how we make money.

Similar Posts